里昂:予中國平安(2318.HK)“跑贏大市”評級 目標價101港元 列為長期首選
里昂發表研究報告,指內地健康保險在過去數年的快速擴張後,新業務價值增長放緩將成為新常態,尤其是長期危疾險。
該行指,在今年宏觀經濟增長放緩、投資回報率偏低,及高收益P2P產品不受政策支持的情況下,相信壽險儲蓄產品將較容易銷售,而有關產品重點在於管理利率風險。
於有關原則下,中國平安(2318.HK)
由於定價機制良好,為該行長期首選,評級“
跑贏大市
”,目標價101港元。壽險股中亦看好中國人壽(2628.HK)
,指其銷售強勁,資產債務管理亦改善,上調其評級自“
跑輸大市
”升級至“
跑贏大市
”,目標價自20港元上調至24港元。另外中國太平(0966.HK)
目標價亦自21港元上調至23港元,評級“
跑贏大市
”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.